Spanish biopharmaceutical company focused on the research and development of new drugs to fight against neurodegenerative dis ... eases using the sea as the source pf chemical entities. The company had a portfolio of compounds in several stages of preclinical and clinical development. The most advanced product, tideglusib, missed the primary point in a phase-IIb clinical trial and, due to the lack of financial resources, the company had to close in 2013. read more